Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12622000525785
Ethics application status
Approved
Date submitted
25/03/2022
Date registered
4/04/2022
Date last updated
24/03/2024
Date data sharing statement initially provided
4/04/2022
Type of registration
Prospectively registered
Titles & IDs
Public title
The effectiveness and acceptability of Breathing Control Training (BCT) for Functional Seizures (FS)
Query!
Scientific title
Breathing Control Training (BCT) as a Treatment for Functional Seizures (FS) - a multi-centre, assessor blinded, randomised controlled efficacy and acceptability trial
Query!
Secondary ID [1]
306768
0
NHMRC APP2000376
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
BREATHS trial
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Functional Seizures
325783
0
Query!
Condition category
Condition code
Mental Health
323121
323121
0
0
Query!
Other mental health disorders
Query!
Neurological
323175
323175
0
0
Query!
Other neurological disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Breathing Control Training (BCT) teaches appropriate rate and depth of breathing and the development of a pattern of breathing appropriate to a person's current physical activity level. The elimination of dysfunctional breathing patterns, including hyperinflation and hyperventilation, is discussed. Diaphragmatic breathing is taught, and emphasis is placed on calm, slow, nasal expiration. Education on stress responses and their interactions with breathing patterns is given. The integration of appropriate breathing and relaxation techniques into daily living activities is encouraged. Initially exercises are taught in a semi-recumbent position, progressing to sitting, then standing, then during everyday activities. Finally, the integration of breathing and relaxation techniques into speech is taught and practiced.
In this project, BCT will be delivered by a respiratory physiotherapist with specific training in this technique at the participant’s primary care hospital, or via Telehealth if required. The physiotherapist will conduct a 60min initial session with the participant (one-on-one) and a 30min refresher (‘booster’) session (one-on-one) 4-weeks later. Participants will be encouraged to practice the learnt BCT techniques daily (5-10 minutes, twice daily) and record their adherence in a calendar style diary. The diary will be be reviewed by the physiotherapist at the booster session and compliance recorded in the participant's case report form, as well if they attended both treatment sessions (initial and booster).
Query!
Intervention code [1]
323220
0
Treatment: Other
Query!
Comparator / control treatment
The control condition, Befriending, is specifically designed to be the control intervention for clinical trials of psychology-based or ‘talking’ therapies. It offers the same clinician contact, and involves meeting and talking with the participant in a supportive, friendly, but non-directive manner. Topics of discussion should be those that are interesting to the participant, and ones that do not bring up negative associations or conflict, for example, talking about movies they like, pets, holidays, cooking, sport, music etc. Befriending has been manualised and its outcomes formally assessed to allow it to serve as a theoretically justified ’placebo’ arm. It has become the standard control arm in therapy trials for mental health, as it matches for expectancy, acceptability, enjoyment and engagement, while delivering no specific benefit on most outcomes.
In this project, the Befriending will be administered by the same clinicians (physiotherapists) at intervals and duration matching the BCT sessions (60min initial one-on-one session and 30min one-on-one 'booster' session 4-weeks later, conducted at the participant's primary care site). The physiotherapist will record the date of attendance (or if the participant failed to attend) for both Befriending sessions in the participant's case report form.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
330888
0
Participant self-reported seizure remission, defined as seizure frequency of zero in the preceding 4-weeks.
Query!
Assessment method [1]
330888
0
Query!
Timepoint [1]
330888
0
Measured 12-weeks post initial treatment session of BCT/Befriending
Query!
Secondary outcome [1]
407929
0
Change in hyperventilation from baseline, measured by the Nijmegen scale of hyperventilation
Query!
Assessment method [1]
407929
0
Query!
Timepoint [1]
407929
0
Nijmegen scale of hyperventilation provided at baseline, and 4-weeks, 12-weeks & 24-weeks post the initial treatment (BCT/Befriending) session
Query!
Secondary outcome [2]
407946
0
Acceptability of BCT assessed by a tailored participant self-report questionnaire
Query!
Assessment method [2]
407946
0
Query!
Timepoint [2]
407946
0
Provided after attending the ‘booster’ BCT treatment session approx. 4-weeks after their baseline session
Query!
Secondary outcome [3]
407947
0
Changes in healthcare utilisation from baseline, measured via a tailored self-report resource use questionnaire (RUQ), as well as changes in health service use obtained from Services Australia (the latter for consenting participants based in Australia) and The Centre for Victorian Data Linkage (CVDL) (for consenting Victorian participants), assessed as a composite secondary outcome where possible.
Query!
Assessment method [3]
407947
0
Query!
Timepoint [3]
407947
0
The RUQ will be provided to participants at baseline, and 12-weeks & 24-weeks post the initial treatment (BCT/Befriending) session. Services Australia data will be requested for the period 12-weeks prior to the participant's randomisation into the trial until the final assessment date (24-weeks post the initial BCT/Befriending treatment session).
Query!
Secondary outcome [4]
407948
0
Changes in quality of life from baseline, measured by the Assessment of Quality of Life Eight Dimension (AQoL 8D)
Query!
Assessment method [4]
407948
0
Query!
Timepoint [4]
407948
0
Provided at baseline, and 4-weeks, 12-weeks & 24-weeks post the initial treatment (BCT/Befriending) session.
Query!
Secondary outcome [5]
407949
0
Changes in depression and anxiety symptoms from baseline, measured by the Hospital Anxiety and Depression Scale (HADS)
Query!
Assessment method [5]
407949
0
Query!
Timepoint [5]
407949
0
Provided at baseline, and 4-weeks, 12-weeks & 24-weeks post the initial treatment (BCT/Befriending) session.
Query!
Secondary outcome [6]
407952
0
Changes in occupational and social functioning from baseline, measured by the Work and Social Adjustment Scale (WSAS)
Query!
Assessment method [6]
407952
0
Query!
Timepoint [6]
407952
0
Provided at baseline, and 4-weeks, 12-weeks & 24-weeks post the initial treatment (BCT/Befriending) session.
Query!
Secondary outcome [7]
407953
0
Safety of BCT assessed by the occurrence of adverse events (AEs). From the investigator's own pilot data (unpublished at present), and randomised-controlled trials of breathing exercises for asthma, BCT’s excellent safety and tolerability profile is evident. Nonetheless, AEs will be reviewed and monitored throughout the trial to further explore BCT’s safety profile in Functional Seizures specifically. Thus, participant's will be asked the following questions:
-If they have received a diagnosis of a new medical condition/disease since baseline
-If they have experienced a worsening in a pre-existing medical condition since baseline
-If any new symptoms have occurred since baseline
-If they have been informed of any abnormal laboratory findings which are identified after randomisation into the trial
Query!
Assessment method [7]
407953
0
Query!
Timepoint [7]
407953
0
AEs will be reviewed 4-weeks, 12-weeks and 24-weeks post the initial treatment (BCT/Befriending) session via an online self-report questionnaire. After reviewing their responses, the research assistant will contact the participant if they require any further information (for example, clarifying onset, duration, severity of the AE) before reporting all AEs to an independent Data and Safety Monitoring Board (DSMB) comprising an epileptologist, psychiatrist and researcher/statistician for review.
Query!
Eligibility
Key inclusion criteria
i) 16 years of age or above
ii) Able to provide written, informed consent
iii) Diagnosis of Functional Seizures (FS; clinically established by an Epileptologist)
iv) Self-reported FS frequency of at least 2 per month
v) English sufficient to complete questionnaires and understand the treatment intervention
Query!
Minimum age
16
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
i) Co-morbid epilepsy (supported by minimum 24 hours of video-EEG)
ii) Currently engaging in other breathing therapy treatments/clinical trials
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants will be allocated sequentially following the randomisation schedule. The randomisation schedule will be stored by an independent statistician, as well as on REDCap, with access permitted to the trial physiotherapists providing the treatment (and who are unblinded during the trial).
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Participants will be individually randomised 1:1 to the BCT or the control arm (Befriending). A randomly permuted block randomisation list will be computer-generated by an independent statistician, stratified by site and hyperventilation (Nijmegen score >23 vs <22).
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
A formal detailed statistical analysis plan for the study will be written prior to unblinding of the database. All analyses will be performed on an intention-to-treat basis and include all randomised participants. Analysis and reporting of the findings may take between 3-6 months.
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
3/01/2023
Query!
Actual
20/02/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
220
Query!
Accrual to date
1
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
22039
0
Austin Health - Austin Hospital - Heidelberg
Query!
Recruitment hospital [2]
22040
0
St Vincent's Hospital (Melbourne) Ltd - Fitzroy
Query!
Recruitment hospital [3]
22041
0
Royal Melbourne Hospital - City campus - Parkville
Query!
Recruitment hospital [4]
22042
0
The Alfred - Melbourne
Query!
Recruitment postcode(s) [1]
37150
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [2]
37151
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [3]
37152
0
3050 - Parkville
Query!
Recruitment postcode(s) [4]
37153
0
3004 - Melbourne
Query!
Recruitment outside Australia
Country [1]
24685
0
New Zealand
Query!
State/province [1]
24685
0
Christchurch
Query!
Funding & Sponsors
Funding source category [1]
311107
0
Government body
Query!
Name [1]
311107
0
National Health & Medical Research Council (NHRMC)
Query!
Address [1]
311107
0
414 La Trobe St
Melbourne VIC 3000
Query!
Country [1]
311107
0
Australia
Query!
Primary sponsor type
University
Query!
Name
University of Melbourne
Query!
Address
Parkville VIC 3010
Query!
Country
Australia
Query!
Secondary sponsor category [1]
312442
0
None
Query!
Name [1]
312442
0
Query!
Address [1]
312442
0
Query!
Country [1]
312442
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
310637
0
Austin Health Human Research Ethics Committee
Query!
Ethics committee address [1]
310637
0
Level 8, Harold Stokes Building
Austin Hospital
145 Studley Rd
Heidelberg VIC 3084
Query!
Ethics committee country [1]
310637
0
Australia
Query!
Date submitted for ethics approval [1]
310637
0
16/02/2022
Query!
Approval date [1]
310637
0
27/06/2022
Query!
Ethics approval number [1]
310637
0
Query!
Summary
Brief summary
We do not understand very clearly what causes Functional Seizures (FS; also known as Non-Epileptic Seizures, or Psychogenic Non-epileptic Seizures) or how to treat them. Previous research suggests that rapid breathing (called hyperventilating) can provoke an episode in some people who have FS. We think that if these people could learn to control their breathing so that they didn’t breathe too quickly this might stop them having seizures. We have tested this on a few people with FS by teaching them something called Breathing Control Training (or ‘BCT’ for short) and found that most of their seizures either stopped or became much less frequent.
BCT is a treatment provided by physiotherapists for people with asthma so they can manage their hyperventilation symptoms, but we want to see if it works for people who experience Functional Seizures (FS). In this research project, we will provide BCT, or a comparison treatment known as 'Befriending', to 220 people with FS so we can determine how many people BCT works for, and which people it does help (so we know who to recommend the treatment to in future). We will also assess if BCT is safe for FS (i.e. does it cause any side effects); if it is acceptable (i.e. do people like it, and find it easy to implement); and if it is an affordable treatment option for people with FS.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
118350
0
Prof Richard Kanaan
Query!
Address
118350
0
Level 10, Lance Townsend Building
Austin Health
145 Studley Rd
Heidelberg VIC 3084
Query!
Country
118350
0
Australia
Query!
Phone
118350
0
+61 394963351
Query!
Fax
118350
0
Query!
Email
118350
0
[email protected]
Query!
Contact person for public queries
Name
118351
0
Prof Richard Kanaan
Query!
Address
118351
0
Level 10, Lance Townsend Building
Austin Health
145 Studley Rd
Heidelberg VIC 3084
Query!
Country
118351
0
Australia
Query!
Phone
118351
0
+61 394963351
Query!
Fax
118351
0
Query!
Email
118351
0
[email protected]
Query!
Contact person for scientific queries
Name
118352
0
Prof Richard Kanaan
Query!
Address
118352
0
Level 10, Lance Townsend Building
Austin Health
145 Studley Rd
Heidelberg VIC 3084
Query!
Country
118352
0
Australia
Query!
Phone
118352
0
+61 394963351
Query!
Fax
118352
0
Query!
Email
118352
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Non-identifiable participant self-report questionnaire data, and clinical characteristics (for those participants who provide specific consent for data sharing).
Query!
When will data be available (start and end dates)?
Immediately following publication; no end date determined
Query!
Available to whom?
Projects that have obtained approval from a registered HREC committee
Query!
Available for what types of analyses?
Analyses that have obtained approval from a registered HREC committee
Query!
How or where can data be obtained?
Please contact the PI, Prof Richard Kanaan via email:
[email protected]
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Doc. No.
Type
Citation
Link
Email
Other Details
Attachment
15567
Clinical study report
[email protected]
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF